Cardio Diagnostics Holdings Inc. announced an agreement with AGEPHA Pharma to advance the precision assessment and management of inflammation associated with coronary heart disease (CHD). AGEPHA Pharma will supply LODOCO® (low-dose colchicine) for a Cardio Diagnostics-sponsored clinical study.
The study will explore the use of Cardio Diagnostics’ PrecisionCHD blood test to identify patients with inflammation-driven CHD and assess their response to LODOCO® over time. PrecisionCHD's six DNA methylation markers map to modifiable drivers of CHD, including inflammation.
This initiative reflects a precision medicine model where diagnosis and treatment are guided by the patient’s unique molecular insights. The dynamic nature of DNA methylation makes PrecisionCHD uniquely suited for non-invasive, repeatable monitoring of inflammation, offering an advantage over traditional imaging.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.